…
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. It operates in two segments, Product Sales and Franchise Service. The company offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) identifies as a China-based biological technology company but provides limited public disclosures. Long-term growth drivers could include rising domestic healthcare demand and broader biotech adoption, but company-specific products and strategy are unclear; investors seeking small-cap China biotech exposure may view it as speculative.
Key risks include limited transparency, low trading liquidity, governance and regulatory uncertainty for China-listed U.S. stocks, and execution risk for a small, early-stage business.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
| Income before tax | -24.08M | 0.79M | 1.18M | 0.19M | -0.48M |
| Net income | -24.36M | 0.48M | 0.85M | 0.19M | -0.48M |
| Selling general administrative | 26.11M | 0.81M | 0.48M | 0.71M | 0.75M |
| Selling and marketing expenses | - | 0.36M | 0.30M | 0.44M | 0.37M |
| Gross profit | 2.38M | 2.19M | 2.15M | 1.41M | 0.62M |
| Reconciled depreciation | 0.11M | 0.02M | 0.02M | 0.03M | 0.04M |
| Ebit | -24.15M | 0.79M | 1.18M | 0.19M | -0.48M |
| Ebitda | -24.04M | 0.82M | 1.20M | 0.22M | -0.44M |
| Depreciation and amortization | 0.11M | 0.02M | 0.02M | 0.03M | 0.04M |
| Operating income | -24.15M | 0.79M | 1.18M | 0.20M | -0.50M |
| Other operating expenses | 26.67M | 1.59M | 1.28M | 1.72M | 1.43M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.28M | 0.31M | 0.33M | -0.00M | 0.00M |
| Interest income | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.01M | 0.00M | 0.00M | 0.00M | -0.00M |
| Income tax expense | 0.28M | 0.31M | 0.33M | -0.00M | - |
| Total revenue | 2.52M | 2.38M | 2.46M | 1.92M | 0.93M |
| Total operating expenses | 26.53M | 1.39M | 0.97M | 1.21M | 1.12M |
| Cost of revenue | 0.14M | 0.20M | 0.31M | 0.51M | 0.31M |
| Total other income expense net | 0.06M | -0.00M | 0.00M | -0.01M | 0.02M |
| Net income from continuing ops | -24.36M | 0.48M | 0.85M | 0.19M | -0.48M |
| Breakdown | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
| Total assets | 5.95M | 3.08M | 2.26M | 2.52M | 0.59M |
| Intangible assets | 0.01M | 0.01M | 0.01M | 0.01M | - |
| Other current assets | 0.33M | 1.12M | 0.34M | 0.07M | 0.00M |
| Total liab | 1.96M | 1.58M | 1.25M | 2.37M | 1.17M |
| Total stockholder equity | 3.99M | 1.51M | 1.01M | 0.15M | -0.58M |
| Other current liab | 1.57M | 0.16M | 0.19M | 0.85M | 0.79M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -24.18M | 0.27M | -0.11M | -0.93M | -1.12M |
| Cash | 3.79M | 0.55M | 1.03M | 0.57M | 0.07M |
| Total current liabilities | 1.88M | 1.52M | 1.24M | 2.37M | 1.16M |
| Current deferred revenue | 0.19M | 0.33M | 0.25M | 1.21M | 0.16M |
| Net debt | -3.61M | -0.48M | -1.00M | -0.55M | -0.04M |
| Short term debt | 0.10M | 0.02M | 0.02M | 0.03M | 0.02M |
| Short long term debt total | 0.18M | 0.07M | 0.03M | 0.03M | 0.04M |
| Other stockholder equity | 28.02M | 1.16M | 1.16M | 1.12M | 0.59M |
| Total current assets | 5.50M | 2.84M | 2.18M | 2.26M | 0.47M |
| Net receivables | 1.30M | 1.11M | 0.71M | 1.53M | 0.08M |
| Inventory | 0.08M | 0.07M | 0.10M | 0.09M | 0.32M |
| Accounts payable | 0.01M | 0.02M | 0.20M | 0.13M | 0.09M |
| Accumulated other comprehensive income | 0.15M | 0.07M | -0.04M | -0.05M | -0.05M |
| Non currrent assets other | 0.02M | 0.00M | 0.01M | 0.18M | 0.01M |
| Non current assets total | 0.45M | 0.24M | 0.09M | 0.25M | 0.12M |
| Capital lease obligations | 0.18M | 0.07M | 0.03M | 0.03M | 0.04M |
| Breakdown | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
| Investments | - | -0.51M | 1.02M | -1.55M | -0.01M |
| Total cashflows from investing activities | -0.57M | -0.51M | 1.02M | -1.55M | -0.01M |
| Net borrowings | 0.01M | -0.07M | -0.72M | 0.14M | 0.24M |
| Total cash from financing activities | 3.74M | -0.96M | -0.68M | 0.67M | 0.50M |
| Net income | -24.36M | 0.48M | 0.85M | 0.19M | -0.48M |
| Change in cash | 3.24M | -0.49M | 0.46M | 0.50M | -0.01M |
| Begin period cash flow | 0.55M | 1.03M | 0.57M | 0.07M | 0.08M |
| End period cash flow | 3.79M | 0.55M | 1.03M | 0.57M | 0.07M |
| Total cash from operating activities | 0.09M | 0.96M | 0.13M | 1.44M | -0.50M |
| Issuance of capital stock | 4.28M | 0.00M | 0.04M | 0.53M | 0.26M |
| Depreciation | 0.11M | 0.02M | 0.02M | 0.03M | 0.04M |
| Other cashflows from investing activities | -0.48M | -0.42M | 1.05M | -1.54M | - |
| Change to inventory | -0.01M | 0.01M | -0.00M | 0.19M | -0.02M |
| Change to account receivables | -0.25M | -0.14M | -0.60M | -0.14M | -0.05M |
| Other cashflows from financing activities | 0.01M | -0.89M | - | - | - |
| Capital expenditures | 0.09M | 0.09M | 0.02M | 0.01M | 0.01M |
| Change in working capital | -0.09M | 0.25M | -0.91M | 1.17M | -0.05M |
| Stock based compensation | 24.07M | 0.00M | 0.00M | - | - |
| Other non cash items | 24.46M | 0.23M | 0.20M | 0.05M | 0.00M |
| Free cash flow | -0.00M | 0.87M | 0.10M | 1.43M | -0.51M |
Sector: Consumer Defensive Industry: Household & Personal Products
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BYAH Park Ha Biological Technology Co., Ltd. |
0.07 3.32% |
2.16 | - | - | 1.38 | 0.89 | 0.03 | 15.52 |
| PG Procter & Gamble Company |
-1.70 1.02% |
165.40 | 23.58 | 22.62 | 4.07 | 7.24 | 4.40 | 16.08 |
| LRLCF L'Oréal S.A |
-25.50 5.05% |
479.50 | 41.14 | 34.25 | 6.52 | 8.59 | 6.67 | 27.76 |
| LRLCY L’Oreal Co ADR |
-1.19 1.17% |
100.37 | 32.44 | 25.64 | 5.16 | 6.03 | 4.79 | 19.51 |
| UL Unilever PLC ADR |
-1.71 2.53% |
66.00 | 21.53 | 16.39 | 2.66 | 7.29 | 2.77 | 12.45 |
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. It operates in two segments, Product Sales and Franchise Service. The company offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.
| Name | Title | Year Born |
|---|---|---|
| Ms. Xiaoqiu Zhang | CEO & Chairman of the Board | 1981 |
| Ms. Xiaoyan Zhu | Chief Financial Officer | 1978 |
| Ms. Xinyu Li | CTO & Product Manager | 1986 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.